Innate Immunity and MASLD

Area of Science:

• Hepatology
• Immunology
• Metabolic Diseases

Background:

• Metabolic dysfunction-associated steatotic liver disease (MASLD) is the leading cause of liver disease globally.
• While often presenting as simple steatosis, MASLD can progress to inflammation, fibrosis, cirrhosis, and hepatocellular carcinoma in approximately 25% of cases.
• Liver inflammation and fibrosis are critical factors influencing patient prognosis.

Purpose of the Study:

• To elucidate the role of innate immunity in the inflammatory processes underlying MASLD.
• To identify key mediators and cellular players involved in MASLD-related liver inflammation.
• To explore the potential of targeting innate immunity pathways for future MASLD therapies.

Main Methods:

• Review of current literature on MASLD pathophysiology, focusing on immune responses.
• Analysis of the involvement of innate immunity mediators (cytokines, adipokines, inflammasomes) and cell types (mononuclear cells, macrophages, NK cells).
• Examination of factors driving innate immunity activation, including metabolic dysregulation and gut microbiota.

Main Results:

• Innate immunity, encompassing proinflammatory cytokines, adipokines, and inflammasomes, is central to MASLD inflammation.
• Key immune cells like mononuclear cells, macrophages, and natural killer cells actively participate in the inflammatory cascade.
• Excess lipids, lipotoxicity, insulin resistance, and gut-derived molecular patterns are identified triggers for innate immune activation in MASLD.

Conclusions:

• The pathophysiology of MASLD-induced liver inflammation is complex, involving intricate innate and adaptive immune responses.
• Targeting innate immunity pathways presents a promising therapeutic avenue for managing MASLD and its severe complications.
• Further research into immune modulation could lead to novel treatment strategies for this prevalent liver condition.